Clinical Trials Browser

OTHER × Prostatic Neoplasms × Ipilimumab × Clear all

NCT02703623 2026-03-06

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04388852 2025-11-21

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Phase 1 Active not recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Prostatic Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT04709276 2025-09-11

CHAMP

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT01688492 2025-08-12

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT03477864 2025-04-29

Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

Phase 1 Withdrawn

Prostatic Neoplasms

NCT05655715 2024-10-16

CheckPRO

Phase 2 Completed

Neoplasms, Prostatic Neoplasms

NCT02113657 2024-05-24

T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer

Phase EARLY_PHASE1 Completed

Neoplasm Metastasis, Prostatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05150236 2023-12-15

ANZUP2001

Phase 2 Unknown

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT01377389 2023-09-29

Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

Phase 2 Terminated

30 enrolled 12 charts

Prostatic Neoplasms

NCT03879122 2022-10-26

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Phase 2/3 Unknown

Prostatic Neoplasms

NCT02601014 2022-02-03

STARVE-PC

Phase 2 Completed

32 enrolled 15 charts

Prostatic Neoplasms

NCT02506114 2021-11-24

Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer

Phase 2 Terminated

15 enrolled 13 charts

Prostatic Neoplasms

NCT01804465 2021-08-18

Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer

Phase 2 Completed

50 enrolled 15 charts

Neoplasms, Prostatic Neoplasms

NCT01832870 2017-08-24

Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT01530984 2015-10-05

Ipilimumab and GMCSF Immunotherapy for Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT01510288 2012-01-16

Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer

Phase 1 Terminated

Prostatic Neoplasms